Keith A. Goldan - Feb 10, 2025 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
Chief Financial Officer
Signature
/s/ Michael A. Metzger, Attorney-in-Fact
Stock symbol
SNDX
Transactions as of
Feb 10, 2025
Transactions value $
-$58,559
Form type
4
Date filed
2/12/2025, 05:16 PM
Previous filing
Feb 7, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNDX Common Stock Sale -$58.6K -3.78K -4% $15.50 90.7K Feb 10, 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units.